Abstract 18971: Radiofrequency Renal Denervation Attenuates Fibrosis in the Setting of Heart Failure
Introduction: Chronic overactivity of the sympathetic nervous system during heart failure contributes to left ventricular (LV) dysfunction, adverse remodeling, and fibrosis. We investigated the effects of radiofrequency renal sympathetic denervation (RDN) on LV function and cardiac fibrosis in a rodent model of hypertension and ischemic heart failure.
Methods: Spontaneously hypertensive rats (SHR) were subjected to 45 min. of coronary artery ligation and reperfusion (Rep) for 12 weeks. At 4 weeks post-Rep, rats underwent either bilateral radiofrequency RDN (n=8) or sham RDN (n=8) procedure using surgical technique. Two- dimensional echocardiograms were performed biweekly. At 12 weeks post-Rep, heart tissues were fixed and stained using Masson’s trichrome for assessment of cardiac fibrosis. RT-PCR was used to quantify relative gene expression of pro-fibrotic factors.
Results: RDN significantly preserved LV ejection fraction at 12 weeks vs. sham (47% ± 2.4 vs. 30% ± 2.5, p < 0.05). RDN also reduced left ventricular (LV) fibrosis (29% ± 2.7 vs. 16% ± 3.0, p < 0.05) and inhibited transition zone expansion of the infarcted region compared to sham (Figure 1A, 1B). Gene quantification revealed that RDN mitigated pro-fibrotic signaling, Col1a1, Col3a1, TGF beta1, IL6, and connective tissue growth factor (CTGF) (Figure 1C).
Conclusion: Radiofrequency RDN preserves LV function in the setting of ischemic heart failure in part via inhibition of myocardial fibrosis. RDN-based therapeutics may prove beneficial for the treatment of heart failure.
Author Disclosures: D.J. Polhemus: None. J. Gao: None. R. Trivedi: None. A. Scarborough: None. T. Goodchild: None. F. Smart: None. D. Kapusta: None. D.J. Lefer: None.
- © 2016 by American Heart Association, Inc.